Yes. Buying PA give you lower entry cost and enjoy higher growth when stock price improve. Some more Preferemce share will entitle to dividend first before dividend is delacroix to ordinary share. Now BIOHLDG is back to track and have major supply contract in hand for next few years .
. Warrant price can go to zero. But this PA is much better than warrant because it is unlikely go to zero. If mother share drop, still can convert to mother share using 11 PA.
BIO HOLDING - Right Issue = 1 Rights for every 15 shares @ 0.20 & 1 ICPS for every 6 shares @ 0.02
BIOHLDG OR & PR listed on 26/04/21 - 04/05/21 OR trading at 0.02 PR trading at 0.005
let say you bought 50,000 OR @ 0.02 = RM 1,000 let say you bought 100,000 PR @ 0.005 = RM 500
You subscribed 50,000 OR = 50,000 shares x 0.20 = RM 10,000 You subscribed 100,000 PR = 100,000 shares x 0.02 = RM 2,000
Today (28/05/21) listing for both BIOHLDG Rights & BIOHLDG-PA
Let say today you sold 50,000 BIOHLDG @ 0.235 = 50,000 x 0.235 = RM 11,750 Let say today you sold 100,000 BIOHLDG-PA @ 0.095 = 100,000 x 0.095 = RM 9,500
Your profit for BIOHOLDING : 11,750 - (10,000 + 1,000) = RM 750
Your profit for BIOHOLDING-PA : 9,500 - ( 2,000 + 500) = RM 7,000
Total profit for both BIOHOLDING Rights & PA = RM 7,750
BIOHLDG-PA subscription price is 0.02 (for those hold mother share and subscribe earlier including the many directors), but its opening price is 0.065 which is a 325% jump in price.
hakubasnow above assumed you can buy BIOHLDG-PR @ 0.005 and later convert to PA. Didn't monitor the OR/PR opening and listing price during their tenure, but I believe it is very unlikely you can get PR @ 0.005 even for RM500, as this implies you are getting a price way below anyone including the directors.
In short, a mini trap to catch retailers attracted by the PA 325% jump in opening price, or possibly warrant traders who bought and convert the OR.
Those who owned mother share and subscribe the PR should be safe though, but I believe the capital invested in PR is quite small so it is nothing to shout about - as compared to the directors who don't need to own huge amount of mother share and are simply entitled to buy OR @ 0.02 with capital 200k each.
"hakubasnow above assumed you can buy BIOHLDG-PR @ 0.005 and later convert to PA. Didn't monitor the OR/PR opening and listing price during their tenure, but I believe it is very unlikely you can get PR @ 0.005 even for RM500, as this implies you are getting a price way below anyone including the directors."
I was helping a friend that asked whether to subscribe or sell his BIOHLDGH-OR & BIOHLDG-PR. He owned 100,000 Bio Holdings and as a result got 6,666 BIOHLDG-OR & 16,666 BIOHLDG-PR. The price for the PR stayed at 0.005 from the commencement (26/04/21) until the last date for trading of rights (03/05/21).
The prices for both OR & PR were correct as I was monitoring it for him during that period of time, hence my calculation should one purchase and subscribe to the rights
Thanks hakubasnow for clarifying the price range of these OR/PR during its listing date.
Anyway, not sure if someone buys OR/PR from open market during the listing period (26/04/21 to 03/05/21), can these be subscribed on time for the mother share and PA? Ie. submit your form to company and hope your application is on time and successful..
If yes those who bought PR @ 0.005 from open market is considered a steal (even directors have to buy @ 0.02), or else whatever you bought just gone like smoke haha..
"Anyway, not sure if someone buys OR/PR from open market during the listing period (26/04/21 to 03/05/21), can these be subscribed on time for the mother share and PA? Ie. submit your form to company and hope your application is on time and successful.."
Shouldn't be a problem as the acceptance and payment date was on 11th May - one week after the OR & PR expired. Ample time to buy bank draft and submit the forms. Anyway my friend applied online using PBB e-Right
Worth to note : Over-subscription rate for the OR was 54.98% Over-subscription rate for the PR was 207.81%
This post by a forumer adds to the concern: Killsthebear Hainan Shifengfu Co. Ltd (“HSCL”), who gave Bioalpha contract, incorporated in Feb 2020, owned few listed companies (or substantial shareholder) m3tech fihb Ritamix (HK) Besides that, after searched Guizhou government website, cant found they win any tender ... sketchy Last Friday Ritamix plunged 82.76% in one day. What's next? 03/08/2020 1:33 AM
Searched online and couldn't find any chinese website or information relating to the 2 China parties who awarded the contract. Though the last 2 quarter reports did announced sales from China contract, but unless the accounts are audited, any Tom Dick Harry accountant also can cook up the books like how Serbadk did??
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
jupiter
1,518 posts
Posted by jupiter > 2021-05-27 10:39 | Report Abuse
等到花儿也谢了....没有破0.245是很难上的ZZZZ